Lantheus Holdings, Inc. $LNTH Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,726,521 shares of the medical equipment provider’s stock after selling 27,983 shares during the quarter. Geode Capital Management LLC owned about 2.60% of Lantheus worth $114,918,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Osterweis Capital Management Inc. acquired a new stake in shares of Lantheus in the second quarter valued at $36,000. Hantz Financial Services Inc. lifted its holdings in shares of Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Lantheus by 324.5% during the fourth quarter. Larson Financial Group LLC now owns 658 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 503 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Lantheus by 71.4% during the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Lantheus by 30.3% during the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 230 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Down 1.8%

Shares of Lantheus stock opened at $100.98 on Friday. The stock has a 50-day moving average price of $88.01 and a 200 day moving average price of $74.96. The company has a market cap of $6.57 billion, a P/E ratio of 24.33 and a beta of -0.03. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $104.00.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same period in the prior year, the business earned $1.53 EPS. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts expect that Lantheus Holdings, Inc. will post 4.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on LNTH. JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Truist Financial reaffirmed a “buy” rating and set a $115.00 target price (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. Citizens Jmp upped their target price on Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a report on Friday, May 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $110.00 target price on shares of Lantheus in a report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.86.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.